Morgan Stanley Adverum Biotechnologies, Inc. Transaction History

Morgan Stanley

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.75 - $1.26 $3.86 Million - $6.49 Million	5,150,396 New	5,150,396 $3.86 Million
Q4 2023 Feb 13, 2024	SELL	$0.75 - $1.26 $1.37 Million - $2.3 Million	-1,825,842 Reduced 26.17%	5,150,396 $3.86 Million
Q3 2023 Nov 15, 2023	BUY	$1.5 - $2.33 $16,209 - $25,177	10,806 Added 0.16%	6,976,238 $10.5 Million
Q2 2023 Aug 14, 2023	BUY	$0.68 - $1.59 $537 - $1,256	790 Added 0.01%	6,965,432 $11.1 Million
Q1 2023 May 15, 2023	SELL	$0.62 - $0.85 $105,654 - $144,848	-170,410 Reduced 2.39%	6,964,642 $5.01 Million
Q4 2022 Feb 14, 2023	SELL	$0.54 - $10.3 $18,637 - $355,483	-34,513 Reduced 0.48%	7,135,052 $4.14 Million
Q3 2022 Nov 14, 2022	SELL	$0.96 - $9.68 $191,919 - $1.94 Million	-199,916 Reduced 2.71%	7,169,565 $6.81 Million
Q2 2022 Oct 27, 2022	BUY	$0.81 - $1.34 $5.68 Million - $9.4 Million	7,012,163 Added 1962.44%	7,369,481 $8.84 Million
Q2 2022 Aug 15, 2022	BUY	$0.81 - $1.34 $5.68 Million - $9.4 Million	7,012,163 Added 1962.44%	7,369,481 $8.84 Million
Q1 2022 Oct 27, 2022	SELL	$1.23 - $1.95 $8.62 Million - $13.7 Million	-7,012,163 Reduced 95.15%	357,318 $469,000
Q1 2022 May 13, 2022	SELL	$1.23 - $1.95 $165,032 - $261,637	-134,173 Reduced 27.3%	357,318 $469,000
Q4 2021 Feb 14, 2022	SELL	$1.74 - $2.4 $1.68 Million - $2.31 Million	-964,153 Reduced 66.24%	491,491 $865,000
Q3 2021 Nov 15, 2021	BUY	$2.08 - $3.6 $3.03 Million - $5.24 Million	1,455,644 New	1,455,644 $3.16 Million

2.53M

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $689M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.